|Bid||41.18 x 800|
|Ask||41.13 x 1300|
|Day's Range||40.90 - 41.54|
|52 Week Range||40.90 - 58.10|
|Beta (5Y Monthly)||0.36|
|PE Ratio (TTM)||15.75|
|Forward Dividend & Yield||1.75 (4.14%)|
|Ex-Dividend Date||May 26, 2022|
|1y Target Est||N/A|
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.